Registry of outcomes for patients with advanced thyroid cancer
Official title: Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.
Run by M.D. Anderson Cancer Center · NCT06507878 · Data updated 2026-11-12
This study looks at how well different treatments work for people with advanced thyroid cancer, comparing those treated at MD Anderson Cancer Center to those treated elsewhere, while also checking how these treatments affect their quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 459 (estimated) |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | December 5, 2024 |
| Main results expected | July 1, 2032 |
| Study ends | July 1, 2034 |
| Registry record updated | September 18, 2026 |
| Trial ID | NCT06507878 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adult patients aged 18 years or older diagnosed with anaplastic thyroid cancer or poorly differentiated thyroid cancer.
✕Probably not a fit
Patients without a diagnosis of anaplastic or poorly differentiated thyroid cancer will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to gather real-world data on patients with advanced thyroid cancer, focusing on their access to treatments and how they respond to commercially available medications outside of clinical trials. The primary objective is to compare overall survival between patients treated at MD Anderson Cancer Center and those treated elsewhere, based on their BRAF status and disease stage. Additionally, the study will evaluate the impact of various therapies on the quality of life of survivors and how sociodemographic factors influence patient outcomes.
Why it matters
Potential benefit: If successful, this study could improve understanding of treatment access and effectiveness for advanced thyroid cancer, leading to better patient outcomes.
How similar studies have gone: Other studies have shown success in gathering real-world data for cancer treatments, indicating that this approach is promising.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: All adult patients aged 18 years or older (with the exception of certain external participant countries where the legal adult age may be different; for example in Singapore, adult majors are defined by age 21 and older) with anaplastic thyroid cancer or poorly differentiated thyroid cancer as their clinical and/ or histological diagnosis will be included. Exclusion Criteria: Patients who do not have anaplastic thyroid cancer or poorly differentiated thyroid cancer on their tumor tissue would be excluded.
Where it's running
-
MD Anderson Cancer Center
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Priyanka C Iyer, MBBS — M.D. Anderson Cancer Center
- Study coordinator: Priyanka C Iyer, MBBS
- Email: piyer@mdanderson.org
- Phone: (832) 291-6069
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
MRG003 added to ongoing treatment after progression in EGFR-positive advanced thyroid cancer
In this study, researchers test whether adding MRG003 to a patient’s current thyroid cancer treatment can shrink tumors for those whose cancer initially responded but later progressed.
-
Selective coverage radiotherapy vs. full coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer
This trial tests whether covering only the tumor-affected area with radiation is as effective as full-area coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer, while aiming to reduce side effects and improve quality of life.
-
Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer
This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).
-
WeChat-supported neck exercises after thyroidectomy
A telehealth program using a WeChat mini program tests if guided neck exercises after thyroid surgery help early recovery and quality of life.
-
Pralsetinib Drug Interaction Study in RET Fusion/MUTATION Positive Solid Tumors
This trial tests whether pralsetinib changes how the body processes certain medicines in adults with RET fusion- or mutation-positive advanced solid tumors.
-
AI chatbot to guide thyroid cancer patients through perioperative education
A new AI chatbot is being tested to see if it helps thyroid cancer patients better prepare for discharge, recover well, and stay engaged in their care compared with traditional education.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.